Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca study shows cost effectiveness of Brilique

AstraZeneca study shows cost effectiveness of Brilique

10th May 2011

AstraZeneca has published data from a study that demonstrates the cost-effectiveness of its acute coronary syndrome treatment Brilique.

Data from a substudy of the Plato clinical trial revealed that the ticagrelor therapy offers a gain in quality-adjusted life years (QALYs) at a cost range of 2,350 to 5,700 euros (2,060 to 4,990 pounds) per QALY, when compared to generic clopidogrel.

This information has played a key role in the drug's success in gaining acceptance for national reimbursement programmes in various nations, including Scotland, with the Scottish Medicines Consortium ratifying the treatment this week.

An assessment covering the remainder of the UK is expected to be delivered by the National Institute for Health and Clinical Excellence later this year.

Tony Zook, executive vice-president of AstraZeneca's global commercial organisation, said: "This new data helps further demonstrate the compelling value proposition ticagrelor offers versus a widely used generic."

Brilique has been approved for the prevention of atherothrombotic events in adult patients with acute coronary syndromes in Europe since December 2010.ADNFCR-8000103-ID-800525508-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.